Abstract 934P
Background
Locally advanced hypopharyngeal carcinoma (LAHC), an aggressive type of head and neck cancer (HNC), generally exhibits poor prognosis. Currently, The programmed death 1 inhibitors, implicated in antitumor activity, emerge as meaningful option in patients with recurrent or metastatic HNC, but the role of camrelizumab remains uncertain. Aim to determine effects and safety of induction therapy of camrelizumab plus TPF (docetaxel, cisplatin, and capecitabine) in LAHC.
Methods
In this single-arm, phase 2, prospective, and single-center trial, patients with T3-4aN0-3M0 LAHC received induction therapy for three cycles: camrelizumab 200 mg on day 1, docetaxel 75 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1-3, capecitabine 800 mg/m2 bid on day 1-14, every three weeks. Patients were assigned to radiotherapy and immunotherapy if they had a complete response or partial response (PR) or assigned to surgery and adjuvant (chemo)radiotherapy if they had stable disease (SD) or progressive disease that was defined by using a tumor volume evaluation system. Camrelizumab was maintained postradiotherapy and immunotherapy for a total of 18 doses. This trial was registered with ClinicalTrials.gov, No. NCT04156698 and is ongoing.
Results
Fifty-one patients were enrolled from May 21, 2020, to April 15, 2023, and the mean duration of follow-up was 16.5 ± 8.7 months. After induction therapy, 42 (82.4%) patients showed PR, and 9 (17.6%) showed SD. Treatment-related adverse events were recorded, leading to treatment suspension in 9 (17.6%) patients but no death. The most common adverse event was alopecia (100%), followed by RCCEP (90.2%), nausea/vomiting (84.3%), and fatigue (58.8%) in the induction therapy period. Twenty-six (51.0%) patients experienced grade 3 or 4 induction therapy-related adverse events. The two-year overall survival, progression-free survival, and laryngeal function preservation rates were 85.5%,72.8%, and 65.4%, respectively.
Conclusions
Camrelizumab plus TPF was well tolerated and demonstrated effective antitumor activity in LAHC, indicating future therapy options of camrelizumab as antitumor MAb for advanced HNC.
Clinical trial identification
NCT04156698.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by the National Natural Science Foundation of China (81502343 and 81972529), Clinical Research Plan of SHDC (SHDC2020CR6011), the Science and Technology Commission of Shanghai Municipality (21Y11900100 and 19411961300).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
868P - A DNA methylation classifier to predict recurrence from clear surgical margins
Presenter: tsima Abou Kors
Session: Poster session 12
869P - Utilizing H&E images and digital pathology to predict response to buparlisib in SCCHN
Presenter: Denis Soulieres
Session: Poster session 12
870P - Dynamic cfHPV DNA changes during induction chemotherapy as an early indicator of treatment responsiveness for locally advanced head and neck cancer patients
Presenter: Yilin Cao
Session: Poster session 12
871P - Detection of circulating tumor DNA in operable loco-regionally advanced HPV-negative head and neck squamous cell carcinoma
Presenter: Ludivine Beaussire
Session: Poster session 12
872P - Prognostic value of pathological intratumor heterogeneity in patients with head and neck squamous cell carcinoma treated with upfront surgery
Presenter: Constance Lamy
Session: Poster session 12
873P - Identification of PIK3CA mutation as a novel predictor of efficacious immunotherapy in head and neck cancer
Presenter: Zongwen Sun
Session: Poster session 12
875P - Proteomic and phosphoproteomic profiling of HNSCC and the role of CDKs as potential drug targets
Presenter: Konrad Klinghammer
Session: Poster session 12
876P - Gene expression analysis in oral potentially malignant disorders (OPMD) with dysplasia identifies patients at high risk of malignant transformation
Presenter: Loris De Cecco
Session: Poster session 12
877P - ROS1 mutations as potential negative predictor for response of immunotherapy in patient with head and neck cancer
Presenter: Yong Yuan
Session: Poster session 12